SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development

European Journal of Medicinal Chemistry

Volumn 86, Issue , 2014, Pages 335-351

  Poce, Giovanna ^a   Cocozza, Martina ^a   Consalvi, Sara ^a   Biava, Mariangela ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

anti TB drugs; MDR TB; Tuberculosis; XDR TB

Indexed keywords

7 (7 AMINO 7 METHYL 5 AZASPIRO[2.4]HEPTAN 5 YL) 6 FLUORO 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMOXICILLIN; AZD 5847; BEDAQUILINE; BENZOTHIAZINONE DERIVATIVE; BETA LACTAM DERIVATIVE; BTZ 038; CIPROFLOXACIN; CLAVULANIC ACID; CLAVULANIC ACID PLUS MEROPENEM; CLOFAZIMINE; DELAMANID; IMIDAZOPIRYDINE AMIDE DERIVATIVE; ISONIAZID; LEVOFLOXACIN; LINEZOLID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITROIMIDAZOLE DERIVATIVE; OPC 6783; OXAZOLIDINONE DERIVATIVE; PRETOMANID; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; SULBACTAM; SUTEZOLID; TAZOBACTAM; TBI 166; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; DRUG DEVELOPMENT; DRUG STRUCTURE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; ANIMAL; CHEMISTRY; DRUG EFFECTS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANIMALS; ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84906997561     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.08.066     Document Type: Review

References (153)

1. Global Tuberculosis Control: WHO Report 2013 World Health Organization Geneva (WHO/HTM/TB/2013.16)
2. A. Zumla, P. Nahid, and S.T. Cole Advances in the development of new tuberculosis drugs and treatment regimens Nat. Rev. 12 2013 388 404
3. A.G. Marriner, A. Nayyar, E. Uh, S.Y. Wong, T. Mukherjee, L.E. Via, M. Carroll, R.L. Edwards, T.D. Gruber, I. Choi, J. Lee, K. Arora, K.D. England, H.I.M. Boshoff, and C.E. Barry III The medicinal chemistry of tuberculosis chemotherapy Top. Med. Chem. 7 2011 47 124
4. J. Cohen Infectious disease. Approval of novel TB drug celebrated-with restraint Science 339 2013 130
5. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for- the-public/human/002614/WC500163211.pdf.
6. N.J. Ryan, and J.H. Lo Delamanid: first global approval Drugs 74 2014 1041 1045
7. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for- the-public/human/002552/WC500166235.pdf.
8. W.R. McClure, and C.L. Cech On the mechanism of rifampicin inhibition of RNA synthesis J. Biol. Chem. 253 1978 8949 8956 (Pubitemid 9117005)
9. M. Ho, B. Hudson, K. Das, E. Arnold, and R. Ebright Structures of RNA polymerase antibiotic complexes Curr. Opin. Struct. Biol. 19 2009 715 723
10. P.A. Aristoff, G.A. Garcia, P.D. Kirchhoff, and H.D.H. Showalter Rifamycins: obstacles and opportunities Tuberculosis 90 2010 388 404
11. A. Bacchi, and G. Pelizzi Comprehensive study on structure-activity relationships of rifamycins: discussion of molecular and crystal structure and spectroscopic and thermochemical properties of rifamycin J. Med. Chem. 41 1998 2319 2332 (Pubitemid 28285734)
12. V. Arioli, M. Berti, G. Carniti, E. Randisi, E. Rossi, and R. Scotti Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative J. Antibiot. 34 1981 1026 1032 (Pubitemid 12243993)
13. W.J. Burman, K. Gallicano, and C. Peloquin Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials Clin. Pharmacokinet. 40 2001 327 341 (Pubitemid 32565595)
14. A. Nakajima, T. Fukami, Y. Kobayashi, A. Watanabe, M. Nakajima, and T. Yokoi Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine Biochem. Pharmacol. 82 2011 1747 1756
15. The tuberculosis trials consortium rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial Lancet 360 2002 528 534
16. T.R. Sterling, M.E. Villarino, A.S. Borisov, N. Shang, F. Gordin, E. Bliven-Sizemore, J. Hackman, C.D. Hamilton, D. Menzies, A. Kerrigan, S.E. Weis, M. Weiner, D. Wing, M.B. Conde, L. Bozeman, C.R. Horsburgh, and R.E. Chaisson Three months of rifapentine and isoniazid for latent tuberculosis infection N. Engl. J. Med. 365 2011 2155 2166
17. S.E. Dorman, S. Goldberg, J.E. Stout, G. Muzanyi, J.L. Johnson, M. Weiner, L. Bozeman, C.M. Heilig, P.J. Feng, R. Moro, M. Narita, P. Nahid, S. Ray, E. Bates, B. Haile, E.L. Nuermberger, A. Vernon, and N.W. Schluger Tuberculosis trials consortium, substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium J. Infect. Dis. 206 2012 1030 1040
18. N.A. Martinson, G.L. Barnes, L.H. Moulton, R. Msandiwa, H. Hausler, M. Ram, J.A. McIntyre, G.E. Gray, and R.E. Chaisson New regimens to prevent tuberculosis in adults with HIV infection N. Engl. J. Med. 365 2011 11 20
19. Rifabutin Tuberculosis 88 2008 145 147
20. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services. http://aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf.
21. B. Williamson, K.E. Dooley, Y. Zhang, D.J. Back, and A. Owen Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine Antimicrob. Agents Chemother. 57 2013 6366 6369
22. A.M. Baciewicz, C.R. Chrisman, C.K. Finch, and T.H. Self Update on rifampin, rifabutin, and rifapentine drug interactions Curr. Med. Res. Opin. 29 2013 1 12
23. World Health Organization Essential medicine selection 17th Expert Committee on the Selection and Use of Essential Medicines 2009
24. F.A. Khan, J. Minion, M. Pai, S. Royce, W. Burman, A.D. Harries, and D. Menzies Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis Clin. Infect. Dis. 50 2010 1288 1299
25. C. Boulanger, E. Hollender, K. Farrell, J.J. Stambaugh, D. Maasen, D. Ashkin, S. Symes, L.A. Espinoza, R.O. Rivero, J.J. Graham, and C.A. Peloquin Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis Clin. Infect. Dis. 49 2009 1305 1311
26. H. Khachi, R. O'Connell, D. Ladenheim, and C. Orkin Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV infected patients with mycobacterial co-infection J. Antimicrob. Chemother. 64 4 2009 871 873
27. K.J. Shaw, and M.R. Barbachyn The oxazolidinones: past, present, and future Ann. N. Y. Acad. Sci. 1241 2011 48 70
28. D. Shinabarger Mechanism of action of the oxazolidinone antibacterial agents Expert Opin. Investig. Drugs 8 1999 1195 1202 (Pubitemid 29410576)
29. K.L. Leach, S.M. Swaney, J.R. Colca, W.G. McDonald, J.R. Blinn, L.M. Thomasco, R.C. Gadwood, D. Shinabarger, L. Xiong, and A.S. Mankin The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria Mol. Cell 26 2007 393 402 (Pubitemid 46687101)
30. M. Biava, G.C. Porretta, D. Deidda, and R. Pompei New trends in development of antimycobacterial compounds Infect. Disord. Drug Targets 6 2006 159 172 (Pubitemid 43881022)
31. M. Tato, E.G. de la Pedrosa, R. Cantón, I. Gómez- García, J. Fortún, P. Martín-Davila, F. Baquero, and E. Gomez-Mampaso In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates Int. J. Antimicrob. Agents 28 2006 75 78
32. L. Alcalá, M.J. Ruiz-Serrano, C.P.F. Turégano, D.G. de Viedma, M. Díaz-Infantes, M. Marín-Arriaza, and E. Bouza In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs Antimicrob. Agents Chemother. 47 2006 416 417 (Pubitemid 36070399)
33. M.H. Cynamon, S.P. Klemens, C.A. Sharpe, and S. Chase Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model Antimicrob. Agents Chemother. 43 1999 1189 1191 (Pubitemid 29214745)
34. K.N. Williams, C.K. Stover, T. Zhu, R. Tasneen, S. Tyagi, J.H. Grosset, and E. Nuermberger Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model Antimicrob. Agents Chemother. 53 2009 1314 1319
35. H. Cox, and N. Ford Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis Int. J. Tuberc. Lung Dis. 16 2012 447 454
36. B. McGee, R. Dietze, D.J. Hadad, L.P.D. Molino, E.L.N. Maciel, W.H. Boom, M. Palaci, J.L. Johnson, and C.A. Peloquin Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis Antimicrob. Agents Chemother. 53 2009 3981 3984
37. A. Di Paolo, P. Malacarne, E. Guidotti, R. Danesi, and M. Del Tacca Pharmacological issues of linezolid: an updated critical review Clin. Pharmacokinet. 49 2010 439 447
38. E. Lee, S. Burger, J. Shah, C. Melton, M. Mullen, F. Warren, and R. Press Linezolid-associated toxic optic neuropathy: a report of 2 cases Clin. Infect. Dis. 37 2003 1389 1391 (Pubitemid 37433638)
39. R. Dietze, D.J. Hadad, B. McGee, L.P. Molino, E.L. Maciel, C.A. Peloquin, D.F. Johnson, S.M. Debanne, K. Eisenach, W.H. Boom, M. Palaci, and J.L. Johnson Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis Am. J. Respir. Crit. Care Med. 178 2008 1180 1185
40. M. Lee, J. Lee, M.W. Carroll, H. Choi, S. Min, T. Song, L.E. Via, L.C. Goldfeder, E. Kang, B. Jin, H. Park, H. Kwak, H. Kim, H.S. Jeon, I. Jeong, J.S. Joh, R.Y. Chen, K.N. Olivier, P.A. Shaw, D. Follmann, S.D. Song, J.K. Lee, D. Lee, C.T. Kim, V. Dartois, S.K. Park, S.N. Cho, and C.E. Barry Linezolid for treatment of chronic extensively drug-resistant tuberculosis N. Engl. J. Med. 36 2012 1508 1518
41. K.C. Chang, C.C. Leung, and C.L. Daley Linezolid for multidrug-resistant tuberculosis Lancet Infect. Dis. 12 2012 502 503
42. C. Kwok-Chiu, Y. Wing-Wai, C. Siu-Wai, L. Chi-Chiu, T. Cheuk-Ming, C. Chi-Hung, P. Kin-Ho Wen, and C.R. Chiu-Yeung Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob. Agents Chemother. 57 2013 3445 3449
43. M.R. Barbachyn, D.K. Hutchinson, S.J. Brickner, M.H. Cynamon, J.O. Kilburn, S.P. Klemens, S.E. Glickman, K.C. Grega, S.K. Hendges, D.S. Toops, C.W. Ford, and G.E. Zurenko Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity J. Med. Chem. 39 1996 680 685 (Pubitemid 26069690)
44. K. Williams, A. Minkowski, O. Amoabeng, C.A. Peloquin, D. Taylor, K. Andries, R.S. Wallis, K.E. Mdluli, and E.L. Nuermberger Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis Antimicrob. Agents Chemother. 56 2012 3114 3120
45. V.M. Reddy, T. Dubuisson, L. Einck, R.S. Wallis, W. Jakubiec, L. Ladukto, S. Campbell, and C.A. Nacy SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro J. Antimicrob. Chemother. 67 2012 1163 1166
46. K.N. Williams, S.J. Brickner, C.K. Stover, T. Zhu, A. Ogden, R. Tasneen, S. Tyagi, J.H. Grosset, and E.L. Nuermberger Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis Am. J. Respir. Crit. Care Med. 180 2009 371 376
47. R.S. Wallis, W.M. Jakubiec, V. Kumar, A.M. Silvia, D. Paige, D. Dimitrova, X. Li, L. Ladutko, S. Campbell, G. Friedland, M. Mitton-Fry, and P.F. Miller Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers J. Infect. Dis. 202 2010 745 751
48. V. Balasubramanian, S. Solapure, H. Iyer, A. Ghosh, S. Sharma, P. Kaur, R. Deepthi, V. Subbulakshmi, V. Ramya, V. Ramachandran, M. Balganesh, L. Wright, D. Melnick, S.L. Butler, and V.K. Sambandamurthy Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis Antimicrob. Agents Chemother. 58 2014 495 502
49. J.E. Hugonnet, and J.S. Blanchard Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate Biochemistry 46 2007 11998 12004 (Pubitemid 350022357)
50. A.R. Flores, L.M. Parsons, and M.S. Pavelka Genetic analysis of the b-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to β-lactam antibiotics Microbiology 151 2005 521 532 (Pubitemid 40277755)
51. J.E. Hugonnet, L.W. Tremblay, H.I. Boshoff, C.E. Barry III, and J.S. Blanchard Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis Science 323 2009 1215 1218
52. K. England, H.I.M. Boshoff, K. Arora, D. Weiner, E. Dayao, D. Schimel, L.E. Via, and C.E. Barry III Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo Antimicrob. Agents Chemother. 56 2012 3384 3387
53. S. Solapure, N. Dinesh, R. Shandil, V. Ramachandran, S. Sharma, D. Bhattacharjee, S. Ganguly, J. Reddy, V. Ahuja, V. Panduga, M. Parab, K.G. Vishwas, N. Kumar, M. Balganesh, and V. Balasubramanian In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis Antimicrob. Agents Chemother. 57 2013 2506 2510
54. M.C. Payen, S. De Wit, C. Martin, R. Sergysels, I. Muylle, Y. Van Laethem, and N. Clumeck Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis Int. J. Tuberc. Lung Dis. 16 2012 558 560
55. WHO Library Cataloguing-in-publication Data, Treatment of Tuberculosis: Guidelines-IV Edition, WHO/HTM/TB/2009.420.
56. R. Cremades, J.C. Rodriguez, E. Garcia-Pachon, A. Galiana, M. Ruiz-Garcia, P. Lopez, and G. Royo Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model J. Antimicrob. Chemother. 66 2011 2281 2283
57. A. Von Groll, A. Martin, P. Jureen, S. Hoffner, P. Vandamme, F. Portaels, J.C. Palomino, and P. Almeida da Silva Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB Antimicrob. Agents Chemother. 53 2009 4498 4500
58. A. Pantel, S. Petrella, N. Veziris, F. Brossier, S. Bastian, V. Jarlier, C. Mayer, and A. Aubry Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis Antimicrob. Agents Chemother. 56 2012 1990 1996
59. T.D. Gootz, and K.E. Brighty Fluoroquinolone antibacterials: SAR mechanism of action, resistance and clinical aspects Med. Res. Rev. 16 1996 433 486 (Pubitemid 26276466)
60. G.S. Tillotson Quinolones: structure-activity relationships and future predictions J. Med. Microbiol. 44 1996 320 324 (Pubitemid 26167176)
61. A.S. Ginsburg, J.H. Grosset, and W.R. Bishai Fluoroquinolones, tuberculosis and resistance Lancet Infect. Dis. 3 2003 432 442
62. C.S. Merle, C. Sismanidis, O.B. Sow, M. Gninafon, J. Horton, O. Lapujade, M.B. Lo, D.A. Mitchinson, C. Perronne, F. Portaels, J. Odhiambo, P. Olliaro, R. Rustomjee, C. Lienhardt, and K. Fielding A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the gatifloxacin for TB (OFLOTUB) project Trials 18 2012 13 61
63. H. Takiff, and E. Guerrero Current prospects for the fluoroquinolones as first-line tuberculosis therapy Antimicrob. Agents Chemother. 55 2011 5421 5429
64. J. Sekiguchi, A. Disratthakit, S. Maeda, and N. Doi Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone Antimicrob. Agents Chemother. 55 2011 3958 3960
65. Z. Ahmad, A. Minkowski, C.A. Peloquin, K.N. Williams, K.E. Mdluli, J.H. Grosset, and E.L. Nuermberger Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis Antimicrob. Agents Chemother. 55 2011 1781 1783
66. V.C. Barry, J.G. Belton, M.L. Conalty, J.M. Denneny, D.W. Edward, J.F. O'Sullivan, D. Twomey, and F. Winder A new series of phenazines (rimino-compounds) with high antituberculosis activity Nature 179 1957 1013 1015
67. V.C. Barry The development of chemotherapeutic agent for tuberculosis V.C. Barry, Chemotherapy of Tuberculosis 1964 Butterworths London, England 46 64
68. M.L. Conalty Methods of preclinical evaluation of antituberculosis drugs V.C. Barry, Chemotherapy of Tuberculosis 1964 Butterworths London, England 150 174
69. T.L. Lemke, and D.A. Villiams Foye's Principles of Medicinal Chemistry 2012
70. J.F. O'Sullivan, M.L. Conalty, and N.E. Morrison Clofazimine analogues active against a clofazimine-resistant organism J. Med. Chem. 31 1988 567 572 (Pubitemid 18070573)
71. N.A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernäs, A.S. Hussain, H.E. Junginger, S.A. Stavchansky, K.K. Midha, V.P. Shah, and G.L. Amidon Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharm. 1 2004 85 96
72. D. Zhang, Y. Lu, K. Liu, B. Liu, J. Wang, G. Zhang, H. Zhang, Y. Liu, B. Wang, M. Zheng, L. Fu, Y. Hou, N. Gong, Y. Lv, C. Li, C.B. Cooper, A.M. Upton, D. Yin, Z. Ma, and H. Huang Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis J. Med. Chem. 55 2012 8409 8417
73. T. Yano, S. Kassovska-Bratinova, J.S. Teh, J. Winkler, K. Sullivan, A. Isaacs, N.M. Schechter, and H. Rubin Reduction of clofazimine by mycobacterial type 2 NADH: quinone oxidoreductase J. Biol. Chem. 286 2011 10276 10287
74. N.E. Morrison, and G.M. Marley Clofazimine binding studies with deoxyribonucleic acid Int. J. Lepr. Mycobact. Dis. 44 1976 475 481 (Pubitemid 8073770)
75. M.M. Krajewska, and R. Anderson An in vitro comparison of the effects of the prooxidative riminophenazines clofazimine and B669 on neutrophil phospholipase A2 activity and superoxide generation J. Infect. Dis. 167 1993 899 904 (Pubitemid 23088260)
76. K.E. Dooley, E.A. Obuku, N. Durakovic, V. Belitsky, C. Mitnick, and E.L. Nuermberger World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J. Infect. Dis. 207 2013 1352 1358
77. Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu, H. Jin, H. Yin, H. Huang, A.M. Upton, and Z. Ma Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation Antimicrob. Agents Chemother. 55 2011 5185 5193
78. S.H. Cho, S. Warit, B. Wan, C.H. Hwang, G.F. Pauli, and S.G. Franzblau Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis Antimicrob. Agents Chemother. 51 2007 1380 1385 (Pubitemid 46586820)
79. J.E.G. Guillemont, J.F.E. Van Gestel, M.G. Venet, H.J.J. Poignet, L.F.B. Decrane, D. Vernier, Quinoline derivatives and their use as mycobacterial inhibitors, WO2004/011436 A1 (2004).
80. K. Andries, P. Verhasselt, J. Guillemont, H.W.H. Gohlmann, J.M. Neefs, H. Winkler, J. Van Gestel, P. Timmerman, M. Zhu, E. Lee, P. Williams, D. de Chaffoy, E. Huitric, S. Hoffner, E. Cambau, C. Truffot-Pernot, N. Lounis, and V. Jarlier A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227 (Pubitemid 40116230)
81. M.R. De Jonge, L.H.M. Koymans, J. Guillemont, A. Koul, and K. Andries A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910 Proteins 67 2007 971 980 (Pubitemid 46753944)
82. E. Huitric, P. Verhasselt, K. Andries, and S. Hoffner In vitro antimicobacterial spectrum of a diarylquinoline ATP synthase inhibitor Antimicrob. Agents Chemother. 51 2007 4202 4204 (Pubitemid 350057830)
83. L.G. Wayne, and L.G. Hayes An in vitro model for sequential study of shift down of Mycobacterium tuberculosis through two stages of non replicating persistence Infect. Immun. 64 1996 2062 2069 (Pubitemid 26165667)
84. A. Koul, L. Vranckx, N. Dendouga, W. Balemans, I. Van den Wyngaert, K. Vergauwen, H.W.H. Gohlmann, R. Willebrords, A. Poncelet, J. Guillemont, D. Bald, and K. Andries Diarylquinolines are bactericidal for dormant Mycobacteria as a result of disturbed ATP homeostasis J. Biol. Chem. 283 2008 25273 25280
85. A.H. Diacon, A. Pym, M. Grobusch, R. Patientia, R. Rustomjee, L. Page-Shipp, C. Pistorius, R. Krause, M. Bogoshi, G. Churchyard, A. Venter, J. Allen, J.C. Palomino, T. De Marez, R.P.G. Van Heeswijk, N. Lounis, P. Meyvisch, J. Verbeeck, W. Parys, K. De Beule, K. Andries, and D.F. Mc Neeley The diarylquinoline TMC207 for multidrug-resistant tuberculosis N. Engl. J. Med. 360 2009 2397 2405
86. A. Matteelli, A. Carvalho, K.E. Dooley, and A. Kritski TMC207: the first compound of a new class of potent anti-tuberculosis drugs Future Microbiol. 5 2010 849 858
87. G.J. Fox, and D. Menzies A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis Infect. Dis. Ther. 2 2013 123 144
88. Center for Disease Control and Prevention Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis MMWR 62 2013 1 16
89. T. Mukherjee, and H. Boshoff Nitroimidazoles for the treatment of TB: past, present and future Future Med. Chem. 11 2011 1427 1454
90. U. Manjunatha, H.I. Boshoff, and C.E. Barry The mechanism of action of PA-824: novel insights from transcriptional profiling Commun. Integr. Biol. 2 2009 215 218
91. R. Singh, U. Manjunatha, H.I. Boshoff, Y.H. Ha, P. Niyomrattanakit, R. Ledwidge, C.S. Dowd, I.Y. Lee, P. Kim, L. Zhang, S. Kang, T.H. Keller, J. Jiricek, and C.E. Barry PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release Science 28 2008 1392 1395 (Pubitemid 352775253)
92. S.E. Cellitti, J. Shaffer, D.H. Jones, T. Mukherjee, M. Gurumurthy, B. Bursulaya, H.I. Boshoff, I. Choi, A. Nayyar, Y.S. Lee, J. Cherian, P. Niyomrattanakit, T. Dick, U.H. Manjunatha, C.E. Barry, G. Spraggon, and B.H. Geierstanger Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824 Structure 20 2012 101 112
93. C.K. Stover, P. Warrener, D.R. VanDevanter, D.R. Sherman, T.M. Arain, M.H. Langhorne, S.W. Anderson, J.A. Towell, Y. Yuan, D.N. McMurray, B.N. Kreiswirth, C.E. Barry, and W.R. Baker A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 22 2000 962 966 (Pubitemid 30435054)
94. P. Kim, L. Zhang, U.H. Manjunatha, R. Singh, S. Patel, J. Jiricek, T.H. Keller, H.I. Boshoff, C.E. Barry, and C.S. Dowd Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles J. Med. Chem. 52 2009 1317 1328
95. P. Kim, S. Kang, H.I. Boshoff, J. Jiricek, M. Collins, R. Singh, U.H. Manjunatha, P. Niyomrattanakit, L. Zhang, M. Goodwin, T. Dick, T.H. Keller, C.S. Dowd, and C.E. Barry Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships J. Med. Chem. 52 2009 1329 1344
96. A. Blaser, B.D. Palmer, H.S. Sutherland, I. Kmentova, S.G. Franzblau, B. Wan, Y. Wang, Z. Ma, A.M. Thompson, and W.A. Denny Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro- 5H-imidazo[2,1-b][1,3]oxazine (PA-824) J. Med. Chem. 55 2012 312 326
97. S. Tyagi, E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis Antimicrob. Agents Chemother. 49 2005 2289 2293 (Pubitemid 40734456)
98. A.J. Lenaerts, V. Gruppo, K.S. Marietta, C.M. Johnson, D.K. Driscoll, N.M. Tompkins, J.D. Rose, R.C. Reynolds, and I.M. Orme Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models Antimicrob. Agents Chemother. 49 2005 2294 2301 (Pubitemid 40734457)
99. A.M. Ginsberg, M.W. Laurenzi, D.J. Rouse, K.D. Whitney, and M.K. Spigelman Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects Antimicrob. Agents Chemother. 53 2009 3720 3725
100. A.M. Ginsberg, M.W. Laurenzi, D.J. Rouse, K.D. Whitney, and M.K. Spigelman Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects Antimicrob. Agents Chemother. 53 2009 3726 3733
101. A.H. Diacon, R. Dawson, M. Hanekom, K. Narunsky, S.J. Maritz, A. Venter, P.R. Donald, C. van Niekerk, K. Whitney, D.J. Rouse, M.W. Laurenzi, A.M. Ginsberg, and M.K. Spigelman Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients Antimicrob. Agents Chemother. 54 2010 3402 3407
102. A.H. Diacon, R. Dawson, J. du Bois, K. Narunsky, A. Venter, P.R. Donald, C. van Niekerk, N. Erondu, A.M. Ginsberg, P. Becker, and M.K. Spigelman Phase II dose-ranging trial of the early bactericidal activity of PA-824 Antimicrob. Agents Chemother. 56 2012 3027 3031
103. M. Matsumoto, H. Hashizume, T. Tomishige, M. Kawasaki, H. Tsubouchi, H. Sasaki, Y. Shimokawa, and M. Komatsu OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice PLoS Med. 3 2006 2131 2144 (Pubitemid 44875946)
104. H. Sasaki, Y. Haraguchi, M. Itotani, H. Kuroda, H. Hashizume, T. Tomishige, M. Kawasaki, M. Matsumoto, M. Komatsu, and H. Tsubouchi Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles J. Med. Chem. 49 2006 7854 7860 (Pubitemid 46033674)
105. M.T. Gler, V. Skripconoka, E. Sanchez-Garavito, H. Xiao, J.L. Cabrera-Rivero, D.E. Vargas-Vasquez, M. Gao, M. Awad, S.K. Park, T.S. Shim, G.Y. Suh, M. Danilovits, H. Ogata, A. Kurve, J. Chang, K. Suzuki, T. Tupasi, W.J. Koh, B. Seaworth, L.J. Geiter, and C.D. Wells Delamanid for multidrug-resistant pulmonary tuberculosis N. Engl. J. Med. 366 2012 2151 2160
106. V. Skripconoka, M. Danilovits, L. Pehme, T. Tomson, G. Skenders, T. Kummik, A. Cirule, V. Leimane, A. Kurve, K. Levina, L.J. Geiter, D. Manissero, and C.D. Wells Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis Eur. Respir. J. 41 2013 1393 1400
107. I. Kmentova, H.S. Sutherland, B.D. Palmer, A. Blaser, S.G. Franzblau, B. Wan, Y. Wang, Z. Ma, W.A. Denny, and A.M. Thompson Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7- dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824) J. Med. Chem. 53 2010 8421 8439
108. W.A. Denny, A.M. Thompson, A. Blaser, B.D. Palmer, Z. Ma, H. Scott Sutherland, I. Kmentova, Nitroimidazooxazines and their uses in anti-tubercular therapy, US 2012/0028973Al.
109. http://www.newtbdrugs.org/project.php?id=48.
110. http://www.clinicaltrials.gov/ct2/show/NCT01218217?term=sq-109&rank= 1.
111. R.E. Lee, M. Protopopova, E. Crooks, R.A. Slayden, M. Terrot, and C.E. Barry 3rd Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates J. Comb. Chem. 5 2003 172 187 (Pubitemid 37123511)
112. M. Protopopova, C. Hanrahan, B. Nikonenko, R. Samala, P. Chen, J. Gearhart, L. Einck, and C.A. Nacy Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines J. Antimicrob. Chemother. 56 2005 968 974 (Pubitemid 41631930)
113. K.A. Sacksteder, M. Protopopova, C.E. Barry 3rd, K. Andries, and C.A. Nacy Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action Future Microbiol. 7 2012 823 837
114. P. Chen, J. Gearhart, M. Protopopova, L. Einck, and C.A. Nacy Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro J. Antimicrob. Chemother. 58 2006 332 337 (Pubitemid 44294944)
115. V.M. Reddy, L. Einck, K. Andries, and C.A. Nacy In vitro interactions between new antitubercular drug candidates SQ109 and TMC207 Antimicrob. Agents Chemother. 54 2010 2840 2846
116. L. Jia, P.E. Noker, L. Coward, G.S. Gorman, M. Protopopova, and J.E. Tomaszewski Interspecies pharmacokinetics and in vitro metabolism of SQ109 Br. J. Pharmacol. 147 2006 476 485 (Pubitemid 43355045)
117. L. Jia, J.E. Tomaszewski, C. Hanrahan, L. Coward, P. Noker, G. Gorman, B. Nikonenko, and M. Protopopova Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug Br. J. Pharmacol. 144 2005 80 87 (Pubitemid 40192564)
118. E. Bogatcheva, C. Hanrahan, B. Nikonenko, G. de los Santos, V. Reddy, P. Chen, F. Barbos, L. Einck, C. Nacy, and M. Protopopova Identification of SQ609 as a lead compound from a library of dipiperidines Bioorg. Med. Chem. Lett. 21 2011 5353 5357
119. H.I. Boshoff, T.G. Myers, B.R. Copp, M.R. McNeil, M.A. Wilson, and C.E. Barry 3rd The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action J. Biol. Chem. 279 2004 40174 40184 (Pubitemid 39258293)
120. L. Jia, L. Coward, G.S. Gorman, P.E. Noker, and J.E. Tomaszewski Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N′-(2- adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv J. Pharmacol. Exp. Ther. 315 2005 905 911 (Pubitemid 41500757)
121. K. Tahlan, R. Wilson, D.B. Kastrinsky, K. Arora, V. Nair, E. Fischer, S.W. Barnes, J.R. Walker, David Alland, Clifton E. Barry 3rd, and H.I. Boshoff SQ109 targets MmpL3, a membrane transporter of trehalosei monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 56 2012 1797 1809
122. K. Lia, L.A. Schurig-Briccio, X. Feng, A. Upadhyay, V. Pujari, B. Lechartier, F.L. Fontes, H. Yang, G. Rao, W. Zhu, A. Gulati, J. Hwan No, G. Cintra, S. Bogue, Y.L. Liu, K. Molohon, P. Orlean, D.A. Mitchell, L. Freitas-Junior, F. Ren, H. Sun, T. Jiang, Y. Li, R.T. Guo, S.T. Cole, R.B. Gennisa, D.C. Crick, and E. Oldfield Multi-target drug discovery for tuberculosis and other infectious diseases J. Med. Chem. 2014 10.1021/jm500131s
123. D. Deidda, G. Lampis, R. Fioravanti, M. Biava, G.C. Porretta, S. Zanetti, and R. Pompei Bactericidal activities of the pyrrole derivative BM212 against multidrugresistant and intramacrophagic Mycobacterium tuberculosis strains Antimicrob. Agents Chemother. 42 1998 3035 3037 (Pubitemid 28501251)
124. V. La Rosa, G. Poce, J. Ortiz Canseco, S. Buroni, M.R. Pasca, M. Biava, R.M. Raju, G.C. Porretta, S. Alfonso, C. Battilocchio, B. Javid, F. Sorrentino, T.R. Ioerger, J.C. Sacchettini, F. Manetti, M. Botta, A. De Logu, E.J. Rubin, and E. De Rossi MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212 Antimicrob. Agents Chemother. 56 2012 324 331
125. M. Biava, R. Fioravanti, G.C. Porretta, D. Deidda, C. Maullu, and R. Pompei New pyrrole derivatives as antimycobacterial agents analogs of BM212 Bioorg. Med. Chem. Lett. 9 1999 2983 2988 (Pubitemid 29499936)
126. M. Biava, G.C. Porretta, D. Deidda, R. Pompei, A. Tafi, and F. Manetti Importance of the thiomorpholine introduction in new pyrrole derivatives as antimycobacterial agents analogues of BM 212 Bioorg. Med. Chem. 11 2003 515 520 (Pubitemid 36132228)
127. M. Biava, G.C. Porretta, D. Deidda, R. Pompei, A. Tafi, and F. Manetti Antimycobacterial compounds. New pyrrole derivatives of BM212 Bioorg. Med. Chem. 12 2004 1453 1458 (Pubitemid 38296536)
128. M. Biava, G.C. Porretta, G. Poce, D. Deidda, R. Pompei, A. Tafi, and F. Manetti Antimycobacterial compounds. Optimization of the BM212 structure, the lead compound for a new pyrrole derivative class Bioorg. Med. Chem. 13 2005 1221 1230 (Pubitemid 40164606)
129. M. Biava, G.C. Porretta, G. Poce, S. Supino, D. Deidda, R. Pompei, P. Molicotti, F. Manetti, and M. Botta Antimycobacterial agents. Novel diarylpirrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity J. Med. Chem. 49 2006 4946 4952 (Pubitemid 44201052)
130. M. Biava, G.C. Porretta, G. Poce, A. De Logu, M. Saddi, R. Meleddu, F. Manetti, E. De Rossi, and M. Botta 1,5-Diphenyl pyrrole derivatives as antimycobacterial agents. Probing the influence on antimycobacterial activity of lipophylic substituents at the phenyl rings J. Med. Chem. 51 2008 3644 3648 (Pubitemid 351875020)
131. M. Biava, G.C. Porretta, G. Poce, A. De Logu, R. Meleddu, E. De Rossi, F. Manetti, and M. Botta 1,5-Diaryl-2-ethyl pyrrole derivatives as antimycobacterial agents: design, synthesis, and microbiological evaluation Eur. J. Med. Chem. 44 2009 4734 4738
132. M. Biava, G.C. Porretta, G. Poce, C. Battilocchio, S. Alfonso, A. De Logu, N. Saddi, F. Manetti, and M. Botta Identification of a novel pyrrole derivative endowed with antimycobacterial activity and protection index comparable to that of the current antitubercular drugs streptomycin and rifampin Bioorg. Med. Chem. 18 2010 8076 8084
133. M. Biava, G.C. Porretta, G. Poce, C. Battilocchio, S. Alfonso, A. De Logu, F. Manetti, and M. Botta Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach Chem. Med. Chem. 6 2011 593 598
134. G. Poce, H.R. Bates, S. Alfonso, M. Cocozza, G.C. Porretta, M. Biava, L. Ballel, J. Rullas, F. Ortega, A. De Logu, A. Agus, V. La Rosa, M.R. Pasca, E. De Rossi, B. Wae, S.G. Franzblau, F. Manetti, M. Botta, and M. Biava Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of
135. A.E. Grzegorzewicz, H. Pham, V.A. Gundi, M.S. Scherman, E.J. North, T. Hess, V. Jones, V. Gruppo, S.E. Born, J. Kordulakova, S.S. Chavadi, C. Morisseau, A.J. Lenaerts, R. E Lee, M.R. McNeil, and M. Jackson Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane Nat. Chem. Biol. 8 2012 334 341
136. S.A. Stanley, S.S. Grant, T. Kawate, N. Iwase, M. Shimizu, C. Wivagg, M. Silvis, E. Kazyanskaya, J. Aquadro, A. Golas, M. Fitzgerald, H. Dai, L. Zhang, and T.D. Hung Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening ACS Chem. Biol. 7 2012 1377 1384
137. M.J. Remuiñán, E. Pérez-Herrán, J. Rullás, C. Alemparte, M. Martínez-Hoyos, D.J. Dow, J. Afari, N. Mehta, J. Esquivias, E. Jiménez, F. Ortega-Muro, M.T. Fraile-Gabaldón, V.L. Spivey, N.J. Loman, M.J. Pallen, C. Constantinidou, D.J. Minick, M. Cacho, M.J. Rebollo-López, C. González, V. Sousa, I. Angulo-Barturen, A. Mendoza-Losana, D. Barros, G.S. Besra, L. Ballell, and N. Cammack Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6′,7′-dihydrospiro[piperidine-4,4′-thieno[3,2-c] pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3 PLoS One 8 2013 e60933
138. S.P. Rao, S.B. Lakshminarayana, R.R. Kondrddi, M. Herve, L.R. Camacho, P. Bifani, S.K. Kalapala, J. Jiricek, N.L. Ma, B.H. Tan, S.H. Ng, M. Nanjundappa, S. Ravindran, P.G. Seah, P. Thayalan, S.H. Lim, B.H. Lee, A. Goh, W.S. Barnes, Z. Chen, K. Gagaring, A.K. Chatterjee, K. Pethe, K. Kuhen, J. Walker, G. Feng, S. Babu, L. Zhang, F. Blasco, D. Beer, M. Weaver, V. Dartois, R. Glynne, T. Dick, P.W. Smith, T.T. Diagana, and U.H. Manjunatha Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis Sci. Trans. Med. 5 2013 214-214
139. M. Zhang, C. Sala, R.C. Hartkoorn, N. Dhar, A. Mendoza-Losana, and S.T. Cole Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis Antimicrob. Agents Chemother. 56 2012 5782 5789
140. V. Makarov, G. Manina, K. Mikusova, U. Möllmann, O. Ryabova, B. Saint-Joanis, J.D. Neera, M.R. Pasca, S. Buroni, A.P. Lucarelli, A. Milano, E. De Rossi, M. Belanova, A. Bobovska, P. Dianiskova, J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J.D. McKinney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J. Albrethsen, I. Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S. Gaonkar, K.R. Shandil, V. Balasubramanian, T. Balganesh, S. Tyagi, J. Grosset, G. Riccardi, and S.T. Cole Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis Science 324 2009 801 804
141. C. Trefzer, M. Rengifo-Gonzalez, M.J. Hinner, P. Schneider, V. Makarov, S.T. Cole, and K. Johnsson Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose-2′-epimerase DprE1 of Mycobacterium tuberculosis J. Am. Chem. Soc. 132 2010 13663 13665
142. C. Trefzer, H. SCE kovierovaÍ, S. Buroni, A. BobovskaÍ, S. Nenci, E. Molteni, F. Pojer, M.R. Pasca, V. Makarov, S.T. Cole, G. Riccardi, K. MikusCE ovaÍ, and K. Johnsson Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2′-Oxidase DprE1 J. Am. Chem. Soc. 134 2012 912 915
143. P.K. Crellin, R. Brammananth, and R.L. Coppel Decaprenylphosphoryl- β-D-ribose-2′-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis PLoS One 6 2011 e16869
144. B. Lechartier, R.C. Hartkoorn, and S.T. Cole In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 56 2012 5790 5793
145. G. Manina, M. Bellinzoni, M.R. Pasca, J. Neres, A. Milano, A.L. Lopes Ribeiro, S. Buroni, H. Škovierová, P. Dianišková, K. Mikušová, J. Marák, V. Makarov, D. Giganti, A. Haouz, A.P. Lucarelli, G. Degiacomi, A. Piazza, L.R. Chiarelli, E. De Rossi, E. Salina, S.T. Cole, P.M. Alzari, and G. Riccardi Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance Mol. Microbiol. 77 2010 1172 1185
146. A.L. Lopes Ribeiro, G. Degiacomi, F. Ewann, S. Buroni, M.L. Incandela, L.R. Chiarelli, G. Mori, J. Kim, M. Contreras-Dominguez, Y. Park, S. Han, P. Brodin, G. Valentini, M. Rizzi, G. Riccardi, and M.R. Pasca Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis PLoS One 6 2011 e26675
147. M.R. Pasca, G. Degiacomi, A.L. Lopes Ribeiro, F. Zara, P. De Mori, B. Heym, M. Mirrione, R. Brerra, L. Pagani, L. Pucillo, P. Troupioti, V. Makarov, S.T. Cole, and G. Riccardi Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones Antimicrob. Agents Chemother. 54 2010 1616 1618
148. V. Makarov, B. Lechartier, M. Zhang, J. Neres, A.M. Van der Sar, S.A. Raadsen, R.C. Hartkoorn, O.B. Ryabova, A. Vocat, L.A. Decosterd, N. Widmer, T. Buclin, W. Bitter, K. Andries, F. Pojer, P.J. Dyson, and S.T. Cole Towards a new combination therapy for tuberculosis with next generation benzothiazinones EMBO Mol. Med. 6 2014 372 383
149. T. Christophe, M. Jackson, H.K. Jeon, D. Fenistein, M. Contreras-Dominguez, J. Kim, A. Genovesio, J.P. Carralot, F. Ewann, E.H. Kim, S.Y. Lee, S. Kang, M.J. Seo, E.J. Park, H. Skovierová, H. Pham, G. Riccardi, J.Y. Nam, L. Marsollier, M. Kempf, M.L. Joly-Guillou, T. Oh, W.K. Shin, Z. No, U. Nehrbass, R. Brosch, S.T. Cole, and P. Brodin High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors PLoS Pathog. 5 2009 e1000645
150. S. Magnet, R.C. Hartkoorn, R. Székely, J. Pató, J.A. Triccas, P. Schneider, C. Szántai-Kis, L. Orfi, M. Chambon, D. Banfi, M. Bueno, G. Turcatti, G. Kéri, and S.T. Cole Leads for antitubercular compounds from kinase inhibitor library screens Tuberc. Edinb. 90 2010 354 360
151. P.S. Shirude, R. Shandil, C. Sadler, M. Naik, V. Hosagrahara, S. Hameed, V. Shinde, C. Bathula, V. Humnabadkar, N. Kumar, J. Reddy, V. Panduga, S. Sharma, A. Ambady, N. Hegde, J. Whiteaker, R.E. McLaughlin, H. Gardner, P. Madhavapeddi, V. Ramachandran, P. Kaur, A. Narayan, S. Guptha, D. Awasthy, C. Narayan, J. Mahadevaswamy, K.G. Vishwas, V. Ahuja, A. Srivastava, K.R. Prabhakar, S. Bharath, R. Kale, M. Ramaiah, N.R. Choudhury, V.K. Sambandamurthy, S. Solapure, P.S. Iyer, S. Narayanan, and M. Chatterji Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo J. Med. Chem. 56 2013 9701 9708
152. F. Wang, D. Sambandan, R. Halder, J. Wang, S.M. Batt, B. Weinrick, I. Ahmad, P. Yang, Y. Zhang, J. Kim, M. Hassani, S. Huszar, C. Trefzer, Z. Ma, T. Kaneko, K.E. Mdluli, S. Franzblau, A.K. Chatterjee, K. Johnsson, K. Mikusova, G.S. Besra, K. Fütterer, S.H. Robbins, S.W. Barnes, J.R. Walker, W.R. Jacobs Jr., and P.G. Schultz Identification of a small molecule with activity against drug-resistant and persistent tuberculosis Proc. Natl. Acad. Sci. U. S. A. 110 2013 2510 2517
153. K. Pethe, P. Bifani, J. Jang, S. Kang, S. Park, S. Ahn, J. Jiricek, J. Jung, H.K. Jeon, J. Cechetto, T. Christophe, H. Lee, M. Kempf, M. Jackson, A.J. Lenaerts, H. Pham, V. Jones, M.J. Seo, Y.M. Kim, M. Seo, J.J. Seo, D. Park, Y. Ko, I. Choi, R. Kim, S.Y. Kim, S.B. Lim, S.A. Yim, J. Nam, H. Kang, H. Kwon, C.T. Oh, Y. Cho, Y. Jang, J. Kim, A. Chua, B.H. Tan, M.B. Nanjundappa, S.P.S. Rao, W.S. Barnes, R. Wintjens, J.R. Walker, S. Alonso, S. Lee, J. Kim, S. Oh, T. Oh, U. Nehrbass, S.J. Han, Z. No, J. Lee, P. Brodin, S.N. Cho, K. Nam, and J. Kim Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis Nat. Med. 19 2013 1157 1162